News & events

News & events

Filter by:
  • News

VarmX enrols first participant in global Phase 3 EquilibriX-S trial evaluating VMX-C001 in urgent surgery

First participant enrolled: EquilibriX-S (NCT07288489), a landmark registrational Phase 3 study of VMX-C001 vs usual pharmacologic care in patients taking...

  • NewsScientific publications

VarmX announces publication of sensitive coagulation assays to assess restoration of coagulation using VMX-C001 in the presence of Factor Xa inhibitors

Key Highlights The collaborative study with Coagulation Profile BV, Maastricht University and Leiden University Medical Center has been accepted for...

  • Conferences & Events

VarmX to Attend LSX World Congress and Bio€quity Europe in Q2 2024

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces that it...
  • Scientific publications

Coagulation assays for assessing direct FXa inhibitor oral anticoagulant reversal effect

Factor Xa direct oral anticoagulants (Fxa-DOACs) require rapid reversal in patients with serious bleeding or prior to urgent surgery.

...
  • Conferences & Events

VarmX to Present Two Abstracts on Lead Compound, VMX-C001, at ISTH 2023 Congress

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces that it...
  • News

VarmX raises €30 million Series B2 financing for IND approval and preparations for pivotal trial

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces it has...
  • News

VarmX Appoints Dr. Jeffrey Lawson, MD, PhD as Chief Scientific Officer

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the appointment...
  • News

VarmX appoints Paul Roos as Chief Financial Officer

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the appointment...
  • Scientific publications

Preclinical safety and toxicokinetics of VMX-C001 – an intravenous bypassing agent for factor Xa inhibitors

VMX-C001, a modified form of human zymogen factor X, is being developed to stop or prevent bleeding in patients taking...

  • News

VarmX to Present New Data at the 2022 ISTH Congress

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announced it will...
  • News

First Subjects Dosed in First-in-Human Trial for VarmX’s Anticoagulant Bypassing Agent, VMX-C001

VarmX, a clinical-stage biotech company focusing on development of innovative approaches for the reversal of anticoagulation, today announced treatment of...

VMX-C001: Transforming the treatment of bleeding in patients taking Factor Xa DOACs

Portfolio